Senseonics (NYSEAMERICAN:SENS) Shares Up 2.7%

Senseonics Holdings Inc (NYSEAMERICAN:SENS) shot up 2.7% on Monday . The company traded as high as $1.13 and last traded at $1.15, 58,482 shares traded hands during mid-day trading. A decline of 97% from the average session volume of 1,726,482 shares. The stock had previously closed at $1.12.

A number of research firms recently weighed in on SENS. BTIG Research reaffirmed a “buy” rating and issued a $2.00 price target on shares of Senseonics in a report on Sunday, August 11th. Stifel Nicolaus started coverage on Senseonics in a research note on Tuesday, October 22nd. They set a “buy” rating and a $2.00 price target on the stock. Piper Jaffray Companies set a $2.00 price target on Senseonics and gave the stock a “hold” rating in a research note on Wednesday, September 4th. Finally, Raymond James cut Senseonics from an “outperform” rating to a “market perform” rating in a research note on Friday, July 5th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $2.00.

The firm has a 50 day simple moving average of $1.07 and a two-hundred day simple moving average of $1.79.

Senseonics (NYSEAMERICAN:SENS) last released its earnings results on Wednesday, August 7th. The company reported ($0.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.01). The company had revenue of $4.61 million during the quarter, compared to the consensus estimate of $4.52 million.

In other Senseonics news, CEO Timothy T. Goodnow bought 88,500 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was purchased at an average price of $1.10 per share, for a total transaction of $97,350.00. Company insiders own 34.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SENS. Bank of Montreal Can lifted its stake in shares of Senseonics by 236.4% during the 2nd quarter. Bank of Montreal Can now owns 14,513 shares of the company’s stock worth $29,000 after acquiring an additional 10,199 shares during the last quarter. D. E. Shaw & Co. Inc. acquired a new position in shares of Senseonics during the second quarter valued at approximately $33,000. Centaurus Financial Inc. raised its holdings in shares of Senseonics by 40,551.2% during the second quarter. Centaurus Financial Inc. now owns 16,667 shares of the company’s stock valued at $34,000 after acquiring an additional 16,626 shares during the last quarter. Royal Bank of Canada raised its holdings in shares of Senseonics by 596.9% during the second quarter. Royal Bank of Canada now owns 29,269 shares of the company’s stock valued at $60,000 after acquiring an additional 25,069 shares during the last quarter. Finally, Raymond James Trust N.A. raised its holdings in shares of Senseonics by 44.9% during the second quarter. Raymond James Trust N.A. now owns 71,000 shares of the company’s stock valued at $145,000 after acquiring an additional 22,000 shares during the last quarter. Institutional investors and hedge funds own 30.66% of the company’s stock.

About Senseonics (NYSEAMERICAN:SENS)

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

Featured Article: Stock Symbols, CUSIP and Other Stock Identifiers

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.